Cellular Biomedicine Names Richard Wang as COO

Cellular Biomedicine Group Inc.

("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today announced the appointment of Richard L. Wang, Ph.D., MBA, PMP as Chief Operating Officer. The announcement comes at an appropriate time as CBMG continues to build its cell therapy platforms and expands its operational facilities. "We are very pleased to welcome Dr. Wang, a seasoned and accomplished industry professional to the Company's management team," said Dr. William (Wei) Cao, Chief Executive Officer for the Company. "He brings tremendous operational, project management, and R&D governance experience from multinational pharmaceutical companies, as well as a scientific background that will support the research of osteoarthritis, oncology and neuroscience therapeutics. His addition reflects our ability to attract successful executives based on the progress and growth potential of our Stem Cell and Immuno-Oncology platforms. Dr. Wang will play a critical role in the management of research collaborations, technology transfers, drug development clinical trials, regulatory affairs, production, and oversight of our multicenter operations. Dr. Wang's end-to-end knowledge and experience in the pharmaceutical R&D, strategy and operational execution both in China and the U.S. will prove to be a strong asset to the Company." "As society increasingly recognizes the importance of immunotherapies and stem cell therapies to treat many unmet medical conditions, CBMG's cellular therapy platforms are very unique and compelling," said Dr. Wang. "I am excited about the opportunity to join CBMG to help lead the company through its next phase of execution in operational excellence, and to work with the leadership team to reach the Company's full potential of globally improving the quality of life for millions of people."